July 7, 2020 | ACAD, Daily JAM, Stock Alerts |
 Stifel analyst Paul Matteis upgraded Acadia Pharmaceuticals (ACAD) to a Buy from a Hold today and raised his target price to $71 from $41. (Shares closed at $57 today, up 6.17%) The upgrade from Matteis was especially powerful since he has been skeptical on the stock...
March 6, 2018 | ACAD, Daily JAM, Stock Alerts |
Today I'm selling Acadia Pharmaceuticals (ACAD) out of my Jubak Picks portfolio. I have a 13.52% loss on this position since I added the shares to the portfolio on November 15, 2016. There are short- and long-range reasons to sell. From a short-range perspective for...
January 9, 2017 | ACAD, Daily JAM, INCY, IONS, Morning Briefing |
JPMorgan Chase holds its big biotech conference today, Monday January 9, and last week’s momentum in the sector as well as likely upbeat guidance to begin the conference at 10:30 a.m. Eastern time from Celgene (CELG) should have the sector on the move.
November 15, 2016 | ACAD, Daily JAM, Stock Alerts |
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the...
November 14, 2016 | ACAD, BMY, Daily JAM, INCY, OGXI |
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the...
